Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30287171.
- Also identified by DOI 10.1053/j.gastro.2018.09.051 and PMC identifier 6340758.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment options for patients with hepatocellular carcinoma are rapidly changing based on positive results from phase 3 trials of targeted and immune-based therapies. More agents designed to target specific pathways and immune checkpoints are in clinical development. Some agents have already been shown to improve outcomes of patients with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the Food and Drug Administration or have been recently approved. We summarize the targeted and immune-based agents in trials of patients with advanced hepatocellular carcinoma and discuss the future of these strategies for liver cancer.
Medical subject headings
- Carcinoma, Hepatocellular
- Immunotherapy
- Liver Neoplasms
- Molecular Targeted Therapy